AbCellera Investor Presentation Deck

CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 14 PORTFOLIO DIVERSIFIED ACROSS MODALITIES, PARTNER SIZE, AND DEAL TYPE. 69* 6 partner-initiated partner-initiated discovery program starts** co-development program starts** 41 partners 9 molecules in the clinic * As of December 31, 2022 ** With downstream participation 12* pre-partnered program starts (TCE, GPCR, ion channel, Covid-19) 2 authorized antibody therapies REGENERON gsk & NOVARTIS GILEAD Ablynx A SANOFI COMPANY EMPIRICO Autolus TACHYON Lilly EVEREST MEDICINES SANOFI moderna Lyell igences Rallybio DENALI teva EQR™ REMAKING MEDICINE Pfizer angios Invetx KODIAK 111111 MERCK BILL & MELINDA GATES foundation

View entire presentation